Drug Profile
Research programme: protease inhibitors - Jiangsu Hengrui/Medivir
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.; Medivir AB
- Class
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in China
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Sweden
- 22 Feb 2007 Medivir and Jiangsu Hengrui Medicine Co. extend research collaboration